CRO & CDMO Partner
To be an in-depth & trusσλ∑©t-worthy CRO & CDM₽λ☆γO Partner
Scientific & Rigorous, inε search of excellence
Innovation & Change♣←,high-efficiency operat↔Ωion
Who We Are
Beijing Hope Pharmaceutical Co.,™α Ltd., established in 2005, is a h→ε©igh-tech enterprise with &quo÷π↔t;chemical drug technology deve×lopment-Process Optimizati≈★on-Regulation registration and approval£σ" as its core competence, ≠✘ and has won the title of "Chiλαλ<na Top 20 Pharmaceutical R&↓♦amp;D Company" f→•§☆or several times. Hope Phar> ≈σma actively builds one-stλ§↔¥op service for drug CRO and CDM§→O, continuously expands its serβσvice areas, and establishes good coop× 'erative relations with some leading phπ¥₹armaceutical companies domestic and a★✘broad.
Hope Pharma has over 20 yearδ☆β's of experience in project evaluation,£>≥ innovation-oriented patent aro≠¥×und design, pre-clinical dλ≈evelopment, clinical trial practice ★, registration, marker authorizati±εσ™on, etc..Our products involve an≠•ti-tumor, anti-depressant, anti-epilepπ®πtic, anxiolytic, cardiovascular and cer✘<γ¥ebrovascular, digestive system, r&'espiratory system and other ✔©¶↓indications.
Until now, more than 140 techn♥¶ology transform, over 90 regi∞★✘₹stration approvals and 73&n₽βbsp;patents has been finished in σ Hope(including subsidiaries) for ®≈∞'past 20 years, and has been rat↕₽ ed as a national high-tech enterpri$≥se.
Focus on medicine development
More than 140+ technology φ♣transfer succeeded
Over 73 invention patents ↔↓×applied
More than 35+ series of produ∑" ™cts Industrial production
Milestones
-
2024
Awarded the title of 'National¥↓∑™ High-tech Enterprise' for 17 consecλ♥"$utive years Awarded the ±βtitle of 'Top 20 Chineseγ↔ Pharmaceutical R&D C↕✘∑ompanies' for 8 conse↔•₽¥cutive years Submitted registration a< pplications for 10 formulation produ®♦÷cts in China, obtaining"→∑✔ over 80 various registration"£∑☆ approvals Obtained registration numbe↔rs for 10 active pharmaceutical ing<✘redients from FDA, CDE,∞α± Taiwan Ministry of He ✔alth and Welfare, and other institδ 'utions Submitted 12 new p"€↕atent applications, with a total→π of over 60 invention patents Achiev♥←γed a cumulative factory technology traβ©nsfer of over 130 items to client compa♦£≈nies
-
2023
Awarded the title of 'National High↕•↑-tech Enterprise' for 16α× consecutive years Awarded the title of←±$₽ 'Top 20 Pharmaceutical R&D Compaπβnies in China' for 7 consecut$↕ive years Has obtainπ↓ed more than 70 clini♦¶•★cal, production license±•→s, and new drug certifica§γtes approved by the Naλ≥tional Medical Products Administra∞λ→tion of China Has submitted more ®₩than 10 international registr♦£"ation applications to the Fπ±DA, EU, etc. Cumulatively ≤§ achieved over a hundred technol< ogy transfers to client com§®γpanies Completed multiple te♠↕chnology achievements trans∞≈formation and industrialized pro♠♠duction of over 30 series prod★ λucts
-
2022
More than 20 new invent₩ion patent applications☆↕ Two raw material drug varietie★∞s registered with CDE trans∞©®↔ferred to A Five formulation vari✘δδeties obtained producti ©≈on licenses Shanghai b∑✘λ♠ranch established to strengthen bu♥δsiness expansion and layout
-
2021
Obtain the first CEP certifica&γ≥↔teObtain CNAS certification certifiπ©cate First submission γ↑of MAH certification a"φ nd obtain B certificate Two r¥↓≠aw material drug varieties C≈®DE transfer to A
-
2020
The R&D office build♠δing of Jinghai Indus★↓±trial Park is officially in ✘×use. Establish a strategic×₽Ω§ partnership with Zezheng P$÷≈harmaceutical.
-
2019
The subsidiary Haimei O÷∞cean was established, and internaΩγ↓€tional business operates indep≠↕₩endently. Submitted registration applications↑✘ to the EU and FDA Ranked among thδγ©e top 20 pharmaceutical R★←&D companies in China for conse ↓δcutive years Pilot unit for integr♣✘→ation of informatizati•₩¥on and industrialization Won the T100 ₹×♣ New Technology and New Product ✔≠Innovation Action Ente£γ÷±rprise Award
-
2018
Establish a strategic Ω♣βpartnership with PPC Jiaseng Consecutiv±✔≥≠ely ranked among the top 2<₩π0 pharmaceutical R&D δ♠₹ companies in China
-
2017
Establish a strategic p♠• artnership with Boteng Pharm←↑aceutical Awarded th≠↔φe title of one of the top 20 phar©λ↕maceutical R&D companies in Chi•←δna
-
2016
The subsidiary Haimeiyuλ&δan was established, and the CRO ✔π®<business operates independently.
-
2015
The subsidiary Haimeitong was✔↔≤ established, and the raw mat™± erials and intermediates business ope≥£&rates independently. Establish an employe e stock ownership platfoσ→rm and complete the shareholding systλ>∞×em transformation.
-
2011
Investing in Shandong Ko≈≤'ngfu Pharmaceutical
-
2008
Establish a strategic partnership wi¥≤¶•th Beihua Hengye
-
2006
Establish a new drug research and dev©σ×☆elopment center
-
2005
Established Haibu Pha ∏rmaceutical
What we do
18
2024-12
16
2024-12
27
2024-11
14
2024-11
Subsidiaries
Beijing HMT Medical Technology CΩ ↑o., Ltd.
API & intermediate bu" siness
Beijing HMY Medical Technolog•→y Co., Ltd.
CRO business
Beijing HMYA Medical Technology §>©Co., Ltd.
International business
Beijing Hope Pharmaceutical Co✔., Ltd.
